NCT07128641View on ClinicalTrials.gov

Odronextamab in Low Tumor Volume Advanced FL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 2, 2027

Study Completion Date

January 2, 2028

Conditions
Follicular LymphomaLymphoma
Interventions
BIOLOGICAL

Odronextamab

A CD20xCD3 bispecific monoclonal antibody, glass vials, via intravenous (into the vein) infusion per protocol.

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Gottfried von Keudell, MD PhD

OTHER